Phoenicis
Mark de Souza, PhD is former CEO / Exec Chair of Lotus Tissue Repair (Shire, $325MM), PellePharm, NFlection Therapeutics, Wings Therapeutics, FIBRX Derm, and others. He is the former VP of Business Development at Dyax (Shire $6B M&A), KALBITOR and TAKHZYRO for hereditary angioedema.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Phoenicis
Phoenicis focuses on developing therapies to provide hope and relief to people living with rare disease.